Study guide
14.2 ED Workflow, Transitions of Care & Boarding Patient Management
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
14.2 ED Workflow, Transitions of Care & Boarding Patient Management
Key Takeaways Explain This Topic AI
ED boarding is associated with delayed doses, more medication errors and higher in-hospital mortality, especially beyond 6–12 hours, so boarding patients need active emergency pharmacist surveillance.
Medication reconciliation must obtain a Best Possible Medication History (BPMH) using at least two independent sources at critical transitions (triage, admission handoff, and discharge) to prevent severe omissions.
Unintentional omission of chronic high-risk therapies during boarding triggers life-threatening crises: antiepileptics precipitate status epilepticus, antiretrovirals foster viral resistance, transplant immunosuppressants risk acute rejection, and holding basal insulin in Type 1 diabetes rapidly triggers ketoacidosis.
Emergency Medicine Pharmacists (EMPs) reduce time-to-critical-medications during bedside resuscitation (cardiac arrest, stroke thrombolysis, RSI, massive transfusion) and prospective order verification.
Discharge stewardship limits acute opioid prescriptions to the shortest effective supply (often 3 days or less, rarely more than 7), offers naloxone when overdose risk is higher (50 MME/day or more, benzodiazepines, substance use or prior overdose), and uses culture callbacks to fix discordant antibiotics.
Last updated: October 2026
14.2 ED Workflow, Transitions of Care & Boarding Patient Management
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around emergency medicine pharmacotherapy principles tested on clinical specialist certification examinations.
The ED Boarding Crisis & Patient Safety Dynamics
Emergency department (ED) boarding is defined as the condition wherein a patient has received a formal medical decision to be admitted to an inpatient bed but remains physically accommodated within the emergency department due to a complete lack of available inpatient inpatient capacity. Boarding represents an operational failure of hospital-wide throughput rather than an isolated ED issue, creating profound clinical hazards for boarding patients and newly presenting emergency arrivals alike.
Clinical Impact of Crowding and Boarding
Medication Administration Delays : Boarding patients experience prolonged delays in receiving critical scheduled home medications and newly ordered inpatient pharmacotherapy. Inpatient orders placed in the electronic health record (EHR) often default to standard inpatient administration times (e.g., 09:00 or 17:00), which may leave an ED boarding patient waiting 8 to 14 hours for their initial inpatient doses unless an emergency pharmacist manually adjusts administration schedules.
Escalated Medication Error Rates : The physical environment of the ED is designed for short-term diagnostic stabilization, not continuous inpatient nursing care. ED nurse-to-patient staffing ratios in crowded departments frequently rise from 1:3 to 1:6 or higher. Under these conditions, studies report substantially more wrong-dose, wrong-time and omitted-dose errors.
Increased Inpatient Mortality : Multiple landmark epidemiologic investigations demonstrate that prolonged ED boarding (>6 to 12 hours) is associated with higher in-hospital mortality in multiple observational studies, prolonged hospital length of stay (LOS), higher rates of secondary hospital-acquired infections, and increased frequency of unexpected ICU transfers occurring within 24 hours of leaving the ED.
High-Risk Transitions of Care & Medication Reconciliation
Transitions of care are vulnerable clinical intersections where communication breakdowns, fragmented information, and shifting clinical responsibilities generate over 50% of all hospital medication errors. The emergency department sits at the epicenter of three high-risk transitions: Community-to-ED (Triage/Arrival) , ED-to-Inpatient (Admission Transfer) , and ED-to-Home (Discharge) .
The Best Possible Medication History (BPMH)
A Best Possible Medication History (BPMH) is a systematic interview and verification process that obtains the most accurate list possible of all medications the patient is currently taking, including drug name, dosage, route, frequency, and time of last dose.
The Multi-Source Rule : A valid BPMH requires consulting at least two independent sources . Relying solely on patient recall or an outdated EHR list is insufficient.
Primary Verification Sources :
Comprehensive, structured patient or caregiver interview.
Outpatient community pharmacy dispensing records (obtained via direct telephone verification or state/regional health information exchange [HIE] pharmacy fill data).
State Prescription Drug Monitoring Program (PDMP) databases (mandatory for controlled substances).
Outpatient specialty clinic notes (e.g., oncology, transplant, nephrology records).
Physical inspection of pill bottles brought to the emergency department. BEST POSSIBLE MEDICATION HISTORY (BPMH) WORKFLOW
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Step 1: Structured Patient / Caregiver Interview │
- │ Cross-examine prescription drugs, OTCs, herbals, and PRN medications │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- ▼
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Step 2: Corroboration via Secondary Objective Source │
- │ Retail pharmacy fill history | State PDMP | Electronic health network │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- ▼
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Step 3: Reconciliation Against Inpatient Admission Orders │
- │ Identify intentional vs unintentional discrepancies (omissions, duplications)│
- └──────────────────────────────────────┬──────────────────────────────────────┘
- ▼
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Step 4: Active Communication & Clarification with Inpatient Provider Team │
- │ Convert oral regimens to IV equivalents when NPO; resume critical basals │
- └─────────────────────────────────────────────────────────────────────────────┘
- Identification of High-Risk Medication Omissions in Boarding Patients
When admitted patients board in the ED for extended durations, non-urgent home medications are frequently discontinued or omitted pending inpatient physician team rounds. For specific therapeutic drug classes, omission is not benign; it is immediately life-threatening .
The Five Critical Omission Classes
Antiepileptic Drugs (AEDs: Levetiracetam, Valproate, Phenytoin, Lacosamide, Carbamazepine) :
Pathophysiology : Antiepileptic agents maintain steady-state serum concentrations to suppress paroxysmal neuronal hypersynchrony. Missing even a single scheduled dose can cause serum drug concentrations to drop below the minimum effective threshold, precipitating breakthrough seizures or refractory status epilepticus.
Pharmacist Action : Reconcile home AED regimens immediately. If the patient is NPO, convert oral formulations to equivalent intravenous dosing (e.g., levetiracetam 1:1 oral to IV, valproate 1:1 oral to IV, lacosamide 1:1 oral to IV). For phenytoin, utilize fosphenytoin IV (1 mg phenytoin equivalent [PE] per 1.5 mg fosphenytoin) to prevent tissue necrosis associated with propylene glycol diluents.
Antiretroviral Therapy (ART for HIV Infection) :
Pathophysiology : HIV replication kinetics are exceptionally rapid. Incomplete adherence or brief interruptions in combination antiretroviral therapy (cART) allow viral rebound and provide selective pressure that fosters irreversible, multidrug-resistant viral mutations.
Pharmacist Action : Never hold ART pending general floor transfer. Never administer partial regimens (e.g., giving 1 drug of a 3-drug fixed-dose single-tablet regimen). Confirm the exact regimen (e.g., Biktarvy [bictegravir/emtricitabine/tenofovir alafenamide], Triumeq [abacavir/dolutegravir/lamivudine]) and ensure immediate dispensing from central pharmacy stock.
Solid Organ Transplant Immunosuppressants (Tacrolimus, Cyclosporine, Mycophenolate) :
Pathophysiology : Calcineurin inhibitors (tacrolimus, cyclosporine) and antimetabolites (mycophenolate mofetil) possess exceptionally narrow therapeutic indices. Rapid drop in trough levels precipitates acute allograft rejection (renal, cardiac, hepatic, or pulmonary), leading to irreversible organ graft failure.
Pharmacist Action : Check 12-hour trough levels immediately if due. If the patient cannot tolerate oral intake, convert tacrolimus to continuous intravenous infusion at one-third to one-fourth (1:3 to 1:4) of the total daily oral dose (due to significant oral first-pass metabolism), administered over 24 hours in a glass or non-PVC container with dedicated IV tubing.
Basal Insulin in Type 1 Diabetes Mellitus (Insulin Glargine, Detemir, Degludec) :
Pathophysiology : In Type 1 Diabetes, absolute endogenous insulin deficiency exists. Basal insulin is required continuously to suppress lipolysis, free fatty acid oxidation, and hepatic ketogenesis. A common, severe clinical misconception is holding basal insulin when a patient is placed on "NPO" status. Withholding basal insulin in a T1D patient triggers acute ketoacidosis (DKA) within 12 to 18 hours, even if blood glucose remains only mildly elevated.
Pharmacist Action : Ensure basal insulin is continued in all Type 1 diabetic patients regardless of NPO status. The basal dose may be cautiously reduced by 20% to 30% if caloric intake is strictly withheld, but basal insulin must never be discontinued entirely .
Chronic Beta-Blockers (Metoprolol Succinate, Carvedilol, Propranolol, Atenolol) :
Pathophysiology : Chronic beta-adrenergic blockade induces compensatory up-regulation and hypersensitization of beta-1 and beta-2 adrenergic receptors. Abrupt cessation leads to uncontrolled adrenergic hyperstimulation, manifesting as rebound tachycardia, hypertensive crisis, acute myocardial ischemia, unstable angina, and malignant ventricular dysrhythmias.
Pharmacist Action : Verify home beta-blocker dosing and resume therapy. If oral intake is prohibited, convert oral metoprolol tartrate or succinate to intravenous metoprolol tartrate (approximate 2.5:1 conversion ratio: 5 mg IV metoprolol every 6 hours is roughly equivalent to 25 mg PO metoprolol tartrate twice daily).
High-Risk Boarding Medication Interventions
High-Risk Drug Class Clinical Manifestation of Omission Urgent Emergency Pharmacist Interventions & Conversions
Antiepileptic Drugs (AEDs) ( Levetiracetam, Lacosamide, Valproate ) Breakthrough focal or generalized seizures; refractory status epilepticus Immediate 1:1 PO to IV conversion; check therapeutic serum drug levels (phenytoin, carbamazepine, valproic acid)
Antiretroviral Therapy (ART) ( Bictegravir, Dolutegravir regimens ) Rapid viral rebound; emergence of multidrug-resistant viral mutations Dispense complete combination regimen; never administer partial components; verify inpatient formulary supply
Transplant Immunosuppressants ( Tacrolimus, Cyclosporine ) Acute cellular and antibody-mediated allograft rejection Convert oral to IV continuous infusion (tacrolimus IV is 1/3 to 1/4 of total daily oral dose); draw trough level
Basal Insulin (T1D) ( Glargine, Detemir, Degludec ) Accelerated lipolysis and ketogenesis; fulminant diabetic ketoacidosis (DKA) Maintain basal insulin despite NPO status (reduce by 20-30% if prolonged NPO); never rely on sliding scale regular insulin alone
Chronic Beta-Blockers ( Metoprolol, Carvedilol ) Adrenergic hypersensitivity; severe rebound tachycardia, angina, MI Convert PO to IV metoprolol (5 mg IV q6h ~ 25 mg PO BID); monitor continuous telemetry and blood pressure
Corticosteroids ( Chronic Prednisone >=20 mg/d ) Acute secondary adrenal crisis (refractory hypotension, shock, hypoglycemia) Initiate stress-dose corticosteroids: Hydrocortisone 50-100 mg IV every 6-8 hours
Parkinson's Medications ( Carbidopa/Levodopa ) Acute severe rigidity, dysphagia, neuroleptic malignant-like syndrome (NMLS) Maintain exact dosing times; consider enteral feeding tube or subcutaneous apomorphine if prolonged NPO
Emergency Medicine Pharmacist (EMP) Direct Clinical Roles
The presence of dedicated, board-certified emergency medicine clinical pharmacists provides direct, tangible improvements in patient survival, resuscitation efficiency, and medication safety.
Bedside Resuscitation Team Member
Cardiopulmonary Arrest (ACLS) : The EMP actively manages resuscitation pharmacotherapy at the bedside: preparing and administering exact weight-based epinephrine, amiodarone, or lidocaine; ensuring appropriate flush volumes (20 mL saline flush following peripheral push); tracking cumulative epinephrine timing (every 3 to 5 minutes); anticipating reversible etiologies ("H's and T's"); and preparing calcium chloride, sodium bicarbonate, or lipid emulsion when toxicology or hyperkalemia is suspected.
Acute Ischemic Stroke : The EMP verifies inclusion/exclusion criteria, screens for recent anticoagulant exposure, calculates exact weight-based dosing for tenecteplase (0.25 mg/kg IV bolus, maximum 25 mg) or alteplase (0.9 mg/kg IV, 10% bolus over 1 min, 90% infusion over 60 min, maximum 90 mg), and administers antihypertensive infusions (nicardipine, clevidipine, labetalol) to achieve target blood pressure (<185/110 mmHg pre-thrombolytic; <180/105 mmHg post-thrombolytic), dramatically reducing door-to-needle (DTN) times.
Rapid Sequence Intubation (RSI) : The EMP assesses patient hemodynamics, shock index, and airway anatomy; selects hemodynamically neutral induction agents (e.g., ketamine or etomidate); calculates ideal versus actual body weight doses for paralytics (rocuronium 1.2 mg/kg or succinylcholine 1.5 mg/kg); and immediately prepares post-intubation analgosedation infusions to prevent awake paralysis.
Trauma & Massive Transfusion : The EMP coordinates rapid activation of massive transfusion protocols (MTP); prepares and administers tranexamic acid (TXA) (1 g IV over 10 minutes within 3 hours of injury, followed by 1 g IV over 8 hours); and manages rapid reversal of pre-injury anticoagulants (4F-PCC, vitamin K, idarucizumab).
Prospective Order Verification & Antimicrobial Stewardship
Real-Time Order Screening : Prospective verification intercepts fatal prescribing errors before drug administration. EMPs screen for renal dosing adjustments, therapeutic duplications, drug-drug interactions, and documented anaphylactic allergies.
Bedside Antimicrobial Optimization : EMPs guide early sepsis empiric antimicrobial selection based on local antibiograms; optimize pharmacokinetics through loading doses (vancomycin 25-30 mg/kg) and extended-infusion beta-lactams; and coordinate rapid diagnostic platforms (e.g., blood culture PCR, MRSA nasal swabs) to de-escalate broad-spectrum therapies within hours.
Clinical Toxicology Consultations : EMPs rapidly evaluate acute toxidromes, recommend targeted laboratory diagnostics, calculate complex antidote infusions (N-acetylcysteine, fomepizole, digoxin Fab, high-dose insulin euglycemia [HIET]), and coordinate care with regional poison control centers.
Discharge Prescribing Stewardship & Culture Callback Systems
Discharge from the emergency department is a critical juncture where inappropriate prescribing choices can lead to patient harm, outpatient treatment failure, or rapid ED recidivism.
Acute Opioid Stewardship Guidelines
Prescribing opioids for acute painful conditions in the ED must comply with evidence-based CDC and ACEP clinical guidelines:
Limiting Duration of Supply : For acute non-cancer pain, outpatient opioid prescriptions must be strictly limited to ≤3 to 7 days supply (typically ≤3 days is sufficient for most acute musculoskeletal or minor trauma pain).
Immediate-Release Only : Only immediate-release (IR) formulations should be prescribed (e.g., oxycodone 5 mg PO or hydrocodone/acetaminophen 5/325 mg PO). Extended-release/long-acting (ER/LA) opioids (such as OxyContin, MS Contin, or transdermal fentanyl) are absolutely contraindicated for acute pain in opioid-naive patients.
Mandatory PDMP Review : Clinicians must query the state Prescription Drug Monitoring Program (PDMP) prior to prescribing controlled substances to identify concurrent opioid prescriptions, undisclosed sedatives, or patterns of multiple-provider episodes.
Naloxone Co-Prescribing : The 2022 CDC opioid prescribing guideline recommends offering take-home naloxone (for example, 4 mg nasal spray, now also available over the counter) when overdose risk is increased, including when:
The prescribed daily opioid dose reaches or exceeds 50 Morphine Milligram Equivalents (MME)/day .
The patient is concurrently prescribed a benzodiazepine, gabapentinoid, or other central nervous system depressant.
The patient has a documented history of substance use disorder (SUD) or prior opioid overdose.
The patient has underlying chronic respiratory disease (e.g., severe COPD, obstructive sleep apnea).
ED Discharge Culture Callback Programs
Emergency patients discharged home on empiric antimicrobials require proactive microbiological follow-up. An emergency-pharmacist-led culture callback program systematically reviews all positive urine, blood, wound, and respiratory cultures 24 to 72 hours post-discharge:
Identification of Discordance : Compare isolated bacterial sensitivities against the discharge empiric prescription (e.g., patient discharged on cephalexin, but urine culture grows Enterobacter cloacae or ESBL-producing E. coli resistant to cephalexin).
Clinical Contact & Intervention : Contact the patient via telephone to evaluate clinical symptom resolution. If asymptomatic and bacteruria was present without systemic symptoms, therapy may be discontinued. If symptomatic and the organism is resistant, the pharmacist contacts the patient's community pharmacy to change the antibiotic to a targeted, susceptible oral agent (e.g., nitrofurantoin or ciprofloxacin) or directs the patient back to the ED if systemic red-flag symptoms (fever, rigors, flank pain, hypotension) have emerged.
High-Risk Discharge Medication Counseling
Direct Oral Anticoagulants (DOACs: Apixaban, Rivaroxaban) : Counsel on exact dosing schedules, taking rivaroxaban with food, managing missed doses, avoiding over-the-counter NSAIDs and aspirin without medical direction, and recognizing signs of major bleeding.
Insulin Regimens : Verify that the patient has access to needles, testing supplies, and a functional glucometer. Demonstrate insulin pen device technique and provide structured education on the "Rule of 15" for hypoglycemia: consume 15 grams of fast-acting carbohydrate (e.g., 4 oz fruit juice or 3-4 glucose tablets), recheck blood glucose in 15 minutes, and repeat if glucose remains <70 mg/dL.
Interprofessional Communication Tools: SBAR & I-PASS
Standardized communication structures eliminate ambiguity during high-velocity clinical handoffs and emergency escalations.
The SBAR Framework (Situational Escalation)
Element Clinical Definition & Purpose Emergency Medicine Example
S - Situation State the immediate, concise reason for the communication "This is the emergency pharmacist calling about Mr. Davis in Bay 4; he is a boarding patient who has developed a sudden focal motor seizure."
B - Background Provide relevant clinical context, admission diagnosis, and history "He was admitted 10 hours ago for a pelvic fracture and has a known history of focal epilepsy. His home levetiracetam 1000 mg PO BID was held on admission."
A - Assessment State your professional clinical evaluation of the current situation "I suspect his seizure is directly driven by subtherapeutic AED levels secondary to omitting his morning levetiracetam dose."
R - Recommendation Propose a clear, actionable, and specific clinical plan "I recommend ordering lorazepam 2 mg IV now to terminate the seizure, followed immediately by an IV push loading dose of levetiracetam 2000 mg IV."
The I-PASS Framework (Standardized Shift & Boarding Handoff)
I - Illness Severity : Categorize patient acuity (e.g., "Stable", "Watcher", "Unstable").
P - Patient Summary : Succinct narrative of events leading to ED admission, active diagnoses, and current clinical course.
A - Action List : Specific time-sensitive tasks to be completed (e.g., "Recheck potassium at 14:00", "Follow up CT abdomen report").
S - Situation Awareness & Contingency Planning : "If-Then" guidance anticipating clinical deterioration (e.g., "If blood pressure drops below 90 mmHg MAP, initiate norepinephrine infusion at 5 mcg/min and notify ICU").
S - Synthesis by Receiver : The receiving clinician provides a brief read-back summarizing the critical action items and contingency plans, ensuring closed-loop communication.